Zoetis up after US FDA's conditional approval for cattle treatment

Zoetis

30/09/2025 20:01

** Shares of animal healthcare company Zoetis ZTS.N rise 2.5% to $146.56

** The U.S. FDA conditionally approved the company's Dectomax-CA1 injectable solution for the prevention and treatment of a type of parasitic condition in cattle

** A New World screwworm larvae infestation in cattle is a dangerous parasitic condition where fly larvae feed on the living tissue of the animal’s wounds, which can lead to infections, systemic failure and even death if not treated promptly

** The FDA granted conditional approval for Dectomax-CA1, which is designed to prevent and treat serious or life-threatening diseases in cattle, citing its eligibility under regulations for such conditions

** Dectomax-CA1 injectable solution is available in 250 ml and 500 ml bottles

     ** Dectomax is already fully approved under a new animal drug application for treatment and control of certain nematode and arthropod parasites in cattle and swine

** Including session's moves, stock down 10.2% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))